Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Investigating the Role of Nonsense-Mediated Decay in High-Grade Serous Ovarian Cancer

EF 2024-25

Résumé
High-grade serous ovarian cancer (HGSOC) is the most common and lethal subtype of ovarian cancer, exhibiting a poor 5-year survival rate of ~30% and accounting for 70-80% of all ovarian cancer deaths. Current cancer therapies such as chemotherapy and immunotherapy have limited success in most HGSOC patients, highlighting the urgent need for new treatment strategies. Nonsense-mediated decay (NMD) is a pathway that healthy cells use to destroy aberrant mRNAs. Interestingly, preliminary data from our lab suggests that HGSOC cells exploit this pathway to avoid being recognized and attacked by the immune system. We observed that when NMD was inhibited in HGSOC cells, aberrant mRNAs that would normally have been destroyed were instead turned into aberrant proteins and presented on the cell surface where they can be detected by the immune system. Some of these aberrant proteins are absent from the surface of normal healthy cells, meaning that they could act as markers of cancer that trigger the immune system to target and kill the cancer cells. Our objective is to study the role of NMD in a mouse model of HGSOC that resembles the human disease. We will investigate if inhibiting NMD results in the appearance of aberrant proteins on the surface of tumour cells, and if the immune system can detect these markers of cancer and attack the tumour. Ultimately, we hope to highlight the potential of targeting NMD as a novel therapeutic strategy to overcome immune evasion in HGSOC and improve outcomes for patients with this challenging cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530011
Name
Yang Dustin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of Nonsense-Mediated Decay in High-Grade Serous Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunology; Cancer Immunotherapy; Immune Evasion Mechanisms; Immunopeptidomics; Mass Spectrometry; Mouse Model; Nonsense-Mediated Decay; Ovarian Cancer; T Cell Activation; Tumour-Specific Antigens
Abstract
High-grade serous ovarian cancer (HGSOC) is the most common and lethal subtype of ovarian cancer, exhibiting a poor 5-year survival rate of ~30% and accounting for 70-80% of all ovarian cancer deaths. Current cancer therapies such as chemotherapy and immunotherapy have limited success in most HGSOC patients, highlighting the urgent need for new treatment strategies. Nonsense-mediated decay (NMD) is a pathway that healthy cells use to destroy aberrant mRNAs. Interestingly, preliminary data from our lab suggests that HGSOC cells exploit this pathway to avoid being recognized and attacked by the immune system. We observed that when NMD was inhibited in HGSOC cells, aberrant mRNAs that would normally have been destroyed were instead turned into aberrant proteins and presented on the cell surface where they can be detected by the immune system. Some of these aberrant proteins are absent from the surface of normal healthy cells, meaning that they could act as markers of cancer that trigger the immune system to target and kill the cancer cells. Our objective is to study the role of NMD in a mouse model of HGSOC that resembles the human disease. We will investigate if inhibiting NMD results in the appearance of aberrant proteins on the surface of tumour cells, and if the immune system can detect these markers of cancer and attack the tumour. Ultimately, we hope to highlight the potential of targeting NMD as a novel therapeutic strategy to overcome immune evasion in HGSOC and improve outcomes for patients with this challenging cancer.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yang, Dustin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~